User menu

Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.

Bibliographic reference Houot, Roch ; Gaulard, Philippe ; Schreiber, Robert ; Mellman, Ira ; Lambotte, Olivier ; et. al. Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.. In: OncoImmunology, Vol. 5, no.7, p. e1186323 (2016)
Permanent URL http://hdl.handle.net/2078.1/182269
  1. Schreiber R. D., Old L. J., Smyth M. J., Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, 10.1126/science.1203486
  2. Gubin Matthew M., Zhang Xiuli, Schuster Heiko, Caron Etienne, Ward Jeffrey P., Noguchi Takuro, Ivanova Yulia, Hundal Jasreet, Arthur Cora D., Krebber Willem-Jan, Mulder Gwenn E., Toebes Mireille, Vesely Matthew D., Lam Samuel S. K., Korman Alan J., Allison James P., Freeman Gordon J., Sharpe Arlene H., Pearce Erika L., Schumacher Ton N., Aebersold Ruedi, Rammensee Hans-Georg, Melief Cornelis J. M., Mardis Elaine R., Gillanders William E., Artyomov Maxim N., Schreiber Robert D., Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, 10.1038/nature13988
  3. Pardoll Drew M., The blockade of immune checkpoints in cancer immunotherapy, 10.1038/nrc3239
  4. Rosenberg Jonathan E, Hoffman-Censits Jean, Powles Tom, van der Heijden Michiel S, Balar Arjun V, Necchi Andrea, Dawson Nancy, O'Donnell Peter H, Balmanoukian Ani, Loriot Yohann, Srinivas Sandy, Retz Margitta M, Grivas Petros, Joseph Richard W, Galsky Matthew D, Fleming Mark T, Petrylak Daniel P, Perez-Gracia Jose Luis, Burris Howard A, Castellano Daniel, Canil Christina, Bellmunt Joaquim, Bajorin Dean, Nickles Dorothee, Bourgon Richard, Frampton Garrett M, Cui Na, Mariathasan Sanjeev, Abidoye Oyewale, Fine Gregg D, Dreicer Robert, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, 10.1016/s0140-6736(16)00561-4
  5. Fehrenbacher Louis, Spira Alexander, Ballinger Marcus, Kowanetz Marcin, Vansteenkiste Johan, Mazieres Julien, Park Keunchil, Smith David, Artal-Cortes Angel, Lewanski Conrad, Braiteh Fadi, Waterkamp Daniel, He Pei, Zou Wei, Chen Daniel S, Yi Jing, Sandler Alan, Rittmeyer Achim, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, 10.1016/s0140-6736(16)00587-0
  6. Ebert Peter J.R., Cheung Jeanne, Yang Yagai, McNamara Erin, Hong Rebecca, Moskalenko Marina, Gould Stephen E., Maecker Heather, Irving Bryan A., Kim Jeong M., Belvin Marcia, Mellman Ira, MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade, 10.1016/j.immuni.2016.01.024
  7. Brahmer Julie, Reckamp Karen L., Baas Paul, Crinò Lucio, Eberhardt Wilfried E.E., Poddubskaya Elena, Antonia Scott, Pluzanski Adam, Vokes Everett E., Holgado Esther, Waterhouse David, Ready Neal, Gainor Justin, Arén Frontera Osvaldo, Havel Libor, Steins Martin, Garassino Marina C., Aerts Joachim G., Domine Manuel, Paz-Ares Luis, Reck Martin, Baudelet Christine, Harbison Christopher T., Lestini Brian, Spigel David R., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer, 10.1056/nejmoa1504627
  8. Prieto P. A., Yang J. C., Sherry R. M., Hughes M. S., Kammula U. S., White D. E., Levy C. L., Rosenberg S. A., Phan G. Q., CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma, 10.1158/1078-0432.ccr-11-1823
  9. Robert Caroline, Soria Jean-Charles, Eggermont Alexander M.M., Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies, 10.1016/j.ejca.2013.07.001
  10. Andrews Stephanie, Andrews Stephanie, Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma, 10.2147/cmar.s31873
  11. Phan G. Q., Yang J. C., Sherry R. M., Hwu P., Topalian S. L., Schwartzentruber D. J., Restifo N. P., Haworth L. R., Seipp C. A., Freezer L. J., Morton K. E., Mavroukakis S. A., Duray P. H., Steinberg S. M., Allison J. P., Davis T. A., Rosenberg S. A., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, 10.1073/pnas.1533209100
  12. Ansell Stephen M., Lesokhin Alexander M., Borrello Ivan, Halwani Ahmad, Scott Emma C., Gutierrez Martin, Schuster Stephen J., Millenson Michael M., Cattry Deepika, Freeman Gordon J., Rodig Scott J., Chapuy Bjoern, Ligon Azra H., Zhu Lili, Grosso Joseph F., Kim Su Young, Timmerman John M., Shipp Margaret A., Armand Philippe, PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma, 10.1056/nejmoa1411087
  13. Garon Edward B., Rizvi Naiyer A., Hui Rina, Leighl Natasha, Balmanoukian Ani S., Eder Joseph Paul, Patnaik Amita, Aggarwal Charu, Gubens Matthew, Horn Leora, Carcereny Enric, Ahn Myung-Ju, Felip Enriqueta, Lee Jong-Seok, Hellmann Matthew D., Hamid Omid, Goldman Jonathan W., Soria Jean-Charles, Dolled-Filhart Marisa, Rutledge Ruth Z., Zhang Jin, Lunceford Jared K., Rangwala Reshma, Lubiniecki Gregory M., Roach Charlotte, Emancipator Kenneth, Gandhi Leena, Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer, 10.1056/nejmoa1501824
  14. Westin Jason R, Chu Fuliang, Zhang Min, Fayad Luis E, Kwak Larry W, Fowler Nathan, Romaguera Jorge, Hagemeister Fredrick, Fanale Michelle, Samaniego Felipe, Feng Lei, Baladandayuthapani Veerabhadran, Wang Zhiqiang, Ma Wencai, Gao Yanli, Wallace Michael, Vence Luis M, Radvanyi Laszlo, Muzzafar Tariq, Rotem-Yehudar Rinat, Davis R Eric, Neelapu Sattva S, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, 10.1016/s1470-2045(13)70551-5
  15. Coulie P. G., Lehmann F., Lethe B., Herman J., Lurquin C., Andrawiss M., Boon T., A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma., 10.1073/pnas.92.17.7976
  16. Corbière Véronique, Chapiro Jacques, Stroobant Vincent, Ma Wenbin, Lurquin Christophe, Lethé Bernard, van Baren Nicolas, Van den Eynde Benoît J., Boon Thierry, Coulie Pierre G., Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases, 10.1158/0008-5472.can-10-2693
  17. Cuende J., Lienart S., Dedobbeleer O., van der Woning B., De Boeck G., Stockis J., Huygens C., Colau D., Somja J., Delvenne P., Hannon M., Baron F., Dumoutier L., Renauld J.-C., De Haard H., Saunders M., Coulie P. G., Lucas S., Monoclonal antibodies against GARP/TGF- 1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo, 10.1126/scitranslmed.aaa1983
  18. Germeau Catherine, Ma Wenbin, Schiavetti Francesca, Lurquin Christophe, Henry Emmanuelle, Vigneron Nathalie, Brasseur Francis, Lethé Bernard, De Plaen Etienne, Velu Thierry, Boon Thierry, Coulie Pierre G., High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens, 10.1084/jem.20041379
  19. Lurquin Christophe, Lethé Bernard, De Plaen Etienne, Corbière Véronique, Théate Ivan, van Baren Nicolas, Coulie Pierre G., Boon Thierry, Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen, 10.1084/jem.20041378
  20. Hawkes Eliza A, Grigg Andrew, Chong Geoff, Programmed cell death-1 inhibition in lymphoma, 10.1016/s1470-2045(15)70103-8
  21. Georgiou K, Blood. 2016 Mar 30
  22. Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, Le Gouill S, Haioun C, Tarte K, Lamy T, Milpied N, Fest T, Damaj G, Clavert A, Al Jijakli A, Banos A, Dutel J-L, Deconinck E, Rodon P, Bouabdallah K, Soubeyran P, Choufi B, Maakaroun A, Tournilhac O, Fleury J, Gressin R, Maisonneuve H, Laribi K, Solal-Celigny P, Moreau P, Rossi J-F, Cartron G, Morineau N, Harousseau J L, Jourdan E, Alexis M, Dreyfus F, Delwail V, Cornillon J, Garidi R, Gyan E, Colombat P, Godemer P, High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial, 10.1038/leu.2014.137
  23. Norfo R., Zini R., Pennucci V., Bianchi E., Salati S., Guglielmelli P., Bogani C., Fanelli T., Mannarelli C., Rosti V., Pietra D., Salmoiraghi S., Bisognin A., Ruberti S., Rontauroli S., Sacchi G., Prudente Z., Barosi G., Cazzola M., Rambaldi A., Bortoluzzi S., Ferrari S., Tagliafico E., Vannucchi A. M., Manfredini R., , miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis, 10.1182/blood-2013-12-544197
  24. Labouré G, Blood 2015; 126:3920; published ahead of print December 3, 2015
  25. Selby M. J., Engelhardt J. J., Quigley M., Henning K. A., Chen T., Srinivasan M., Korman A. J., Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells, 10.1158/2326-6066.cir-13-0013
  26. KÖHLER G., MILSTEIN C., Continuous cultures of fused cells secreting antibody of predefined specificity, 10.1038/256495a0
  27. Sagiv-Barfi Idit, Kohrt Holbrook E. K., Czerwinski Debra K., Ng Patrick P., Chang Betty Y., Levy Ronald, Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK, 10.1073/pnas.1500712112
  28. Gajewski Thomas F, Schreiber Hans, Fu Yang-Xin, Innate and adaptive immune cells in the tumor microenvironment, 10.1038/ni.2703
  29. Kadin M., Hodgkin Lymphoma, 10.1182/ashimagebank-2002-100484
  30. Green M. R., Rodig S., Juszczynski P., Ouyang J., Sinha P., O'Donnell E., Neuberg D., Shipp M. A., Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy, 10.1158/1078-0432.ccr-11-1942
  31. Roemer MG, J Clin Oncol (2016)
  32. Savage K. J., The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma, 10.1182/blood-2003-06-1841
  33. Feuerhake F., NF B activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes, 10.1182/blood-2004-12-4901
  34. Green M. R., Monti S., Rodig S. J., Juszczynski P., Currie T., O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T. R., Kutok J. L., Shipp M. A., Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, 10.1182/blood-2010-05-282780
  35. Shi Min, Roemer Margaretha G.M., Chapuy Bjoern, Liao Xiaoyun, Sun Heather, Pinkus Geraldine S., Shipp Margaret A., Freeman Gordon J., Rodig Scott J., Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain : , 10.1097/pas.0000000000000297
  36. Chen B. J., Chapuy B., Ouyang J., Sun H. H., Roemer M. G. M., Xu M. L., Yu H., Fletcher C. D. M., Freeman G. J., Shipp M. A., Rodig S. J., PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies, 10.1158/1078-0432.ccr-13-0855
  37. Pangault C, Amé-Thomas P, Ruminy P, Rossille D, Caron G, Baia M, De Vos J, Roussel M, Monvoisin C, Lamy T, Tilly H, Gaulard P, Tarte K, Fest T, Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFH–B cell axis, 10.1038/leu.2010.223
  38. Amé-Thomas P, Le Priol J, Yssel H, Caron G, Pangault C, Jean R, Martin N, Marafioti T, Gaulard P, Lamy T, Fest T, Semana G, Tarte K, Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells, 10.1038/leu.2011.301
  39. Launay E, Pangault C, Bertrand P, Jardin F, Lamy T, Tilly H, Tarte K, Bastard C, Fest T, High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis, 10.1038/leu.2011.266
  40. Ame-Thomas P., Hoeller S., Artchounin C., Misiak J., Braza M. S., Jean R., Le Priol J., Monvoisin C., Martin N., Gaulard P., Tarte K., CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells, 10.1182/blood-2015-02-625152
  41. Bombardieri M., Barone F., Lucchesi D., Nayar S., van den Berg W. B., Proctor G., Buckley C. D., Pitzalis C., Inducible Tertiary Lymphoid Structures, Autoimmunity, and Exocrine Dysfunction in a Novel Model of Salivary Gland Inflammation in C57BL/6 Mice, 10.4049/jimmunol.1201216
  42. Amin R., Mourcin F., Uhel F., Pangault C., Ruminy P., Dupre L., Guirriec M., Marchand T., Fest T., Lamy T., Tarte K., DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma, 10.1182/blood-2015-04-640912
  43. Kohrt H. E., Houot R., Goldstein M. J., Weiskopf K., Alizadeh A. A., Brody J., Muller A., Pachynski R., Czerwinski D., Coutre S., Chao M. P., Chen L., Tedder T. F., Levy R., CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies, 10.1182/blood-2010-08-301945
  44. Kohrt Holbrook E., Houot Roch, Weiskopf Kipp, Goldstein Matthew J., Scheeren Ferenc, Czerwinski Debra, Colevas A. Dimitrios, Weng Wen-Kai, Clarke Michael F., Carlson Robert W., Stockdale Frank E., Mollick Joseph A., Chen Lieping, Levy Ronald, Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer, 10.1172/jci61226
  45. Kohrt Holbrook E., Colevas A. Dimitrios, Houot Roch, Weiskopf Kipp, Goldstein Matthew J., Lund Peder, Mueller Antonia, Sagiv-Barfi Idit, Marabelle Aurelien, Lira Ruth, Troutner Emily, Richards Lori, Rajapaska Amanda, Hebb Jonathan, Chester Cariad, Waller Erin, Ostashko Anton, Weng Wen-Kai, Chen Lieping, Czerwinski Debra, Fu Yang-Xin, Sunwoo John, Levy Ronald, Targeting CD137 enhances the efficacy of cetuximab, 10.1172/jci73014
  46. Houot Roch, Kohrt Holbrook E., Marabelle Aurélien, Levy Ronald, Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy, 10.1016/j.it.2011.07.003
  47. Houot R., Levy R., T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy, 10.1182/blood-2008-07-170274
  48. Ghirelli Cristina, Hagemann Thorsten, Targeting immunosuppression for cancer therapy, 10.1172/jci69999
  49. Brody Joshua D., Ai Weiyun Z., Czerwinski Debra K., Torchia James A., Levy Mia, Advani Ranjana H., Kim Youn H., Hoppe Richard T., Knox Susan J., Shin Lewis K., Wapnir Irene, Tibshirani Robert J., Levy Ronald, In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study, 10.1200/jco.2010.28.9793
  50. Okazaki Taku, Chikuma Shunsuke, Iwai Yoshiko, Fagarasan Sidonia, Honjo Tasuku, A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application, 10.1038/ni.2762
  51. Armand Philippe, Nagler Arnon, Weller Edie A., Devine Steven M., Avigan David E., Chen Yi-Bin, Kaminski Mark S., Holland H. Kent, Winter Jane N., Mason James R., Fay Joseph W., Rizzieri David A., Hosing Chitra M., Ball Edward D., Uberti Joseph P., Lazarus Hillard M., Mapara Markus Y., Gregory Stephanie A., Timmerman John M., Andorsky David, Or Reuven, Waller Edmund K., Rotem-Yehudar Rinat, Gordon Leo I., Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial, 10.1200/jco.2012.48.3685
  52. Westin Jason R, Chu Fuliang, Zhang Min, Fayad Luis E, Kwak Larry W, Fowler Nathan, Romaguera Jorge, Hagemeister Fredrick, Fanale Michelle, Samaniego Felipe, Feng Lei, Baladandayuthapani Veerabhadran, Wang Zhiqiang, Ma Wencai, Gao Yanli, Wallace Michael, Vence Luis M, Radvanyi Laszlo, Muzzafar Tariq, Rotem-Yehudar Rinat, Davis R Eric, Neelapu Sattva S, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, 10.1016/s1470-2045(13)70551-5
  53. Ansell SM, J Clin Oncol, 32, TPS8613. (2014)
  54. Advani Ranjana, Forero-Torres Andres, Furman Richard R., Rosenblatt Joseph D., Younes Anas, Ren Hong, Harrop Kate, Whiting Nancy, Drachman Jonathan G., Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma, 10.1200/jco.2008.21.3017
  55. Shang Bin, Liu Yao, Jiang Shu-juan, Liu Yi, Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis, 10.1038/srep15179
  56. Hodi F. S., Butler M., Oble D. A., Seiden M. V., Haluska F. G., Kruse A., MacRae S., Nelson M., Canning C., Lowy I., Korman A., Lautz D., Russell S., Jaklitsch M. T., Ramaiya N., Chen T. C., Neuberg D., Allison J. P., Mihm M. C., Dranoff G., Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients, 10.1073/pnas.0712237105
  57. Quezada S. A., CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells, 10.1172/jci27745
  58. Simpson Tyler R., Li Fubin, Montalvo-Ortiz Welby, Sepulveda Manuel A., Bergerhoff Katharina, Arce Frederick, Roddie Claire, Henry Jake Y., Yagita Hideo, Wolchok Jedd D., Peggs Karl S., Ravetch Jeffrey V., Allison James P., Quezada Sergio A., Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma, 10.1084/jem.20130579
  59. Selby M. J., Engelhardt J. J., Quigley M., Henning K. A., Chen T., Srinivasan M., Korman A. J., Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells, 10.1158/2326-6066.cir-13-0013
  60. Sutmuller Roger P.M., van Duivenvoorde Leonie M., van Elsas Andrea, Schumacher Ton N.M., Wildenberg Manon E., Allison James P., Toes Rene E.M., Offringa Rienk, Melief Cornelis J.M., Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses, 10.1084/jem.194.6.823
  61. Hodi F. Stephen, O'Day Steven J., McDermott David F., Weber Robert W., Sosman Jeffrey A., Haanen John B., Gonzalez Rene, Robert Caroline, Schadendorf Dirk, Hassel Jessica C., Akerley Wallace, van den Eertwegh Alfons J.M., Lutzky Jose, Lorigan Paul, Vaubel Julia M., Linette Gerald P., Hogg David, Ottensmeier Christian H., Lebbé Celeste, Peschel Christian, Quirt Ian, Clark Joseph I., Wolchok Jedd D., Weber Jeffrey S., Tian Jason, Yellin Michael J., Nichol Geoffrey M., Hoos Axel, Urba Walter J., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, 10.1056/nejmoa1003466
  62. Robert Caroline, Thomas Luc, Bondarenko Igor, O'Day Steven, Weber Jeffrey, Garbe Claus, Lebbe Celeste, Baurain Jean-François, Testori Alessandro, Grob Jean-Jacques, Davidson Neville, Richards Jon, Maio Michele, Hauschild Axel, Miller Wilson H., Gascon Pere, Lotem Michal, Harmankaya Kaan, Ibrahim Ramy, Francis Stephen, Chen Tai-Tsang, Humphrey Rachel, Hoos Axel, Wolchok Jedd D., Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, 10.1056/nejmoa1104621
  63. Bulliard Yannick, Jolicoeur Rose, Zhang Jimin, Dranoff Glenn, Wilson Nicholas S, Brogdon Jennifer L, OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy, 10.1038/icb.2014.26
  64. Coe David, Begom Shaima, Addey Caroline, White Matthew, Dyson Julian, Chai Jian-Guo, Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy, 10.1007/s00262-010-0866-5
  65. Smith P., DiLillo D. J., Bournazos S., Li F., Ravetch J. V., Mouse model recapitulating human Fc  receptor structural and functional diversity, 10.1073/pnas.1203954109
  66. Pasero Christine, Speiser Daniel E, Derré Laurent, Olive Daniel, The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy, 10.1016/j.coph.2012.03.001
  67. Gertner-Dardenne J., Castellano R., Mamessier E., Garbit S., Kochbati E., Etienne A., Charbonnier A., Collette Y., Vey N., Olive D., Human V 9V 2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts, 10.4049/jimmunol.1103710
  68. Gertner-Dardenne J., Fauriat C., Orlanducci F., Thibult M.-L., Pastor S., Fitzgibbon J., Bouabdallah R., Xerri L., Olive D., The co-receptor BTLA negatively regulates human V 9V 2 T-cell proliferation: a potential way of immune escape for lymphoma cells, 10.1182/blood-2012-11-464685
  69. Dahan Rony, Sega Emanuela, Engelhardt John, Selby Mark, Korman Alan J., Ravetch Jeffrey V., FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis, 10.1016/j.ccell.2015.08.004
  70. Boyerinas B., Jochems C., Fantini M., Heery C. R., Gulley J. L., Tsang K. Y., Schlom J., Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells, 10.1158/2326-6066.cir-15-0059
  71. Brahmer Julie R., Drake Charles G., Wollner Ira, Powderly John D., Picus Joel, Sharfman William H., Stankevich Elizabeth, Pons Alice, Salay Theresa M., McMiller Tracee L., Gilson Marta M., Wang Changyu, Selby Mark, Taube Janis M., Anders Robert, Chen Lieping, Korman Alan J., Pardoll Drew M., Lowy Israel, Topalian Suzanne L., Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates, 10.1200/jco.2009.26.7609
  72. Hamid Omid, Robert Caroline, Daud Adil, Hodi F. Stephen, Hwu Wen-Jen, Kefford Richard, Wolchok Jedd D., Hersey Peter, Joseph Richard W., Weber Jeffrey S., Dronca Roxana, Gangadhar Tara C., Patnaik Amita, Zarour Hassane, Joshua Anthony M., Gergich Kevin, Elassaiss-Schaap Jeroen, Algazi Alain, Mateus Christine, Boasberg Peter, Tumeh Paul C., Chmielowski Bartosz, Ebbinghaus Scot W., Li Xiaoyun Nicole, Kang S. Peter, Ribas Antoni, Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma, 10.1056/nejmoa1305133
  73. Yang Xiaoyu, Wang Fengqiang, Zhang Ying, Wang Larry, Antonenko Svetlana, Zhang Shuli, Zhang Yi Wei, Tabrizifard Mohammad, Ermakov Grigori, Wiswell Derek, Beaumont Maribel, Liu Liming, Richardson Daisy, Shameem Mohammed, Ambrogelly Alexandre, Comprehensive Analysis of the Therapeutic IgG4 Antibody Pembrolizumab: Hinge Modification Blocks Half Molecule Exchange In Vitro and In Vivo, 10.1002/jps.24620
  74. Schumacher T. N., Schreiber R. D., Neoantigens in cancer immunotherapy, 10.1126/science.aaa4971
  75. Zitvogel Laurence, Apetoh Lionel, Ghiringhelli François, Kroemer Guido, Immunological aspects of cancer chemotherapy, 10.1038/nri2216
  76. Stagg J., Loi S., Divisekera U., Ngiow S. F., Duret H., Yagita H., Teng M. W., Smyth M. J., Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy, 10.1073/pnas.1016569108
  77. Verbrugge I., Hagekyriakou J., Sharp L. L., Galli M., West A., McLaughlin N. M., Duret H., Yagita H., Johnstone R. W., Smyth M. J., Haynes N. M., Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies, 10.1158/0008-5472.can-12-0210
  78. Twyman-Saint Victor Christina, Rech Andrew J., Maity Amit, Rengan Ramesh, Pauken Kristen E., Stelekati Erietta, Benci Joseph L., Xu Bihui, Dada Hannah, Odorizzi Pamela M., Herati Ramin S., Mansfield Kathleen D., Patsch Dana, Amaravadi Ravi K., Schuchter Lynn M., Ishwaran Hemant, Mick Rosemarie, Pryma Daniel A., Xu Xiaowei, Feldman Michael D., Gangadhar Tara C., Hahn Stephen M., Wherry E. John, Vonderheide Robert H., Minn Andy J., Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer, 10.1038/nature14292